glp-1 in development What is the pipeline for future medications for obesity? GLP-1 Reporter Cells | Incretin
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Farrs J., Pujol A., Coma M., Ruiz J.L., Naval J., Mas J.M., Molins A., Fondevila J., Aloy P
Conclusion : Retatrutide offers a wide range of health benefits, making it a promising medication in various areas of healthcare
While thirst is not a direct adverse effect of semaglutide according to the UK SmPC, individual responses to medication vary, and patients should monitor their symptoms carefully
However, data is extremely limited
